Загрузка...
Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions
An understanding of vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways has greatly changed the way metastatic renal cell carcinoma (RCC) is treated. Based on available phase III randomized trials, anti-VEGF agents such as sunitinib, sorafenib, bevacizumab-bas...
Сохранить в:
| Главные авторы: | , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
SAGE Publications
2010
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3126007/ https://ncbi.nlm.nih.gov/pubmed/21789125 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834009352498 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|